

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

SAMSUNG BIOEPIS CO., LTD.  
Petitioner,

v.

REGENERON PHARMACEUTICALS, INC.  
Patent Owner.

Patent No. 11,253,572

---

*Inter Partes* Review No. IPR2023-00884

---

**DECLARATION OF DARALYN J. DURIE IN SUPPORT OF  
MOTION FOR ADMISSION *PRO HAC VICE***

I, Daralyn J. Durie, declare as follows:

1. I am an attorney licensed to practice law in the state of California and am admitted to practice before the United States Court of Appeals for the Federal Circuit. I am also admitted to practice before the United States Court of Appeals for the 1st Circuit, the United States Court of Appeals for the 3rd Circuit, the United States Court of Appeals for the 8th Circuit, the United States Court of Appeals for the 9th Circuit, the United States District Courts in the Northern, Central, Eastern, and Southern Districts of California, and the Eastern District of Texas, among other courts.

2. I am a member in good standing in all jurisdictions where I have been admitted to practice.

3. I have never been suspended or disbarred from practice before any court or administrative body.

4. I have never had an application denied for admission before any court or administrative body.

5. I have never had any sanctions or contempt citations imposed by any court or administrative body.

6. I have read and agree to comply with the Office Patent Trial Practice Guide and the Board's Rules of Practice for Trials set forth in 37 C.F.R. part 42.

7. I affirm my agreement before the USPTO to be subject to the USPTO

IPR2023-00884

Rules of Professional Conduct 37 C.F.R. §§ 11.101 *et seq.* and disciplinary jurisdiction under 37 C.F.R. § 11.19(a).

8. I have applied to appear *pro hac vice* in the following proceedings before the USPTO in the last three (3) years:

- a. *Celltrion Inc. v. Regeneron Pharmaceuticals Inc.*, IPR2023-00462  
(*pro hac vice* granted; pending);
- b. *Samsung Bioepis Co., LTD v. Regeneron Pharmaceuticals Inc.*,  
IPR2023-00739 (*pro hac vice* pending);
- c. *Mylan Pharmaceuticals, Inc. v. Regeneron Pharmaceuticals Inc.*,  
IPR2022-01225 (consolidated with *Celltrion, Inc. v. Regeneron  
Pharmaceuticals, Inc.*, IPR2023-00532) (*pro hac vice* granted);
- d. *Mylan Pharmaceuticals, Inc. Celltrion Inc., and Samsung Bioepis  
Co., Ltd. v. Regeneron Pharmaceuticals Inc.*, IPR2022-01226  
(consolidated with *Celltrion, Inc. v. Regeneron Pharmaceuticals,  
Inc.*, IPR2023-00533 and *Samsung Bioepis Co., Ltd. v. Regeneron  
Pharmaceuticals, Inc.*, IPR2023-00566) (*pro hac vice* granted);
- e. *Dropworks, Inc. v. Lawrence Livermore National Security LLC*,  
IPR2021-00218 (*pro hac vice* granted; terminated);
- f. *Dropworks, Inc. v. Lawrence Livermore National Security LLC*,

IPR2023-00884

IPR2021-00302 (*pro hac vice* granted; terminated);

g. *Dropworks, Inc. v. President and Fellows of Harvard College*,

IPR2021-00828 (*pro hac vice* granted; terminated).

9. I have been a partner at the law firm of Morrison & Foerster LLP since I joined the firm on January 1, 2023. I was previously a partner at the law firm of Durie Tangri LLP from 2009 through December 31, 2022. I have worked on patent litigation matters for over 20 years. I have handled patent cases relating to biotechnology for more than 16 years, and in this time I have handled many patent cases relating to methods of treatment using antibodies.

10. I am familiar with the subject matter at issue in this proceeding. I have been engaged by the Patent Owner to represent the Patent Owner before the Board in this proceeding. I have undertaken the study of *inter alia* the '572 Patent, the Petition for *Inter Partes* Review, and the art cited in the Petition. I am also familiar with the co-pending litigations identified by the Petitioner in the Petition for *Inter Partes* Review, Paper 2 at 6. I have represented Patent Owner in patent matters relating to Eylea® since September 2022. I have acquired a substantial understanding of the underlying legal and technological issues at stake in these proceedings.

IPR2023-00884

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of U.S. Patent No. 11,253,572.

Dated: December 20, 2023

By: /Daralyn J. Durie/  
Daralyn J. Durie  
MORRISON & FOERSTER LLP  
425 Market Street  
San Francisco, California 94105  
Tel: (415) 268-6055